Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Emcure Pharmaceuticals announced the commercial launch of Poviztra®, semaglutide injection, across India. With this launch Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra®, a second brand of Novo Nordisk's Semaglutide injection for weight management. Available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dosing of 2.4 mg, the products will be priced starting Rs 8790/- per month (4 weekly doses). It comes in a state-of-the-art pen device that provides the convenience of simple administration of precise dosing.
Semaglutide injection (Poviztra®) is supported by extensive clinical evidence from the STEP and SELECT clinical trial programmes and has demonstrated robust real-world use. Globally, the molecule has nearly a decade of market presence, 38 million patient-years* of exposure, and a strong safety and efficacy profile backed by comprehensive data.
Poviztra® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Poviztra® is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. In clinical trials, the semaglutide formulation achieved weight loss of more than 20% in many patients.
Emcure Pharmaceuticals Ltd, Kaynes Technology India Ltd, Vedant Fashions Ltd, Westlife Foodworld Ltd are among the other stocks to see a surge in volumes on BSE today, 18 November 2025.
Mphasis Ltd notched up volume of 190.73 lakh shares by 10:46 IST on BSE, a 1692.99 fold spurt over two-week average daily volume of 11266 shares. The stock slipped 1.35% to Rs.2,653.10. Volumes stood at 9551 shares in the last session.
Emcure Pharmaceuticals Ltd registered volume of 52.38 lakh shares by 10:46 IST on BSE, a 247.89 fold spurt over two-week average daily volume of 21131 shares. The stock slipped 3.22% to Rs.1,350.40. Volumes stood at 24247 shares in the last session.
Kaynes Technology India Ltd witnessed volume of 6.38 lakh shares by 10:46 IST on BSE, a 22.68 times surge over two-week average daily volume of 28120 shares. The stock dropped 4.55% to Rs.5,958.95. Volumes stood at 22769 shares in the last session.
Vedant Fashions Ltd recorded volume of 2.12 lakh shares by 10:46 IST on BSE, a 20.5 times surge over two-week average daily volume of 10360 shares. The stock lost 0.96% to Rs.620.00. Volumes stood at 8419 shares in the last session.
Westlife Foodworld Ltd clocked volume of 31652 shares by 10:46 IST on BSE, a 6.73 times surge over two-week average daily volume of 4702 shares. The stock gained 0.08% to Rs.544.25. Volumes stood at 8886 shares in the last session.
Novo Nordisk India and Emcure Pharma today announced a strategic partnership to launch Poviztra®, semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India.
Wegovy® (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity.1 In clinical trials, 1 in 3 participants on Wegovy® experienced weight loss of over 20%.2 Poviztra® is a second brand of Wegovy®.
This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviz tra®, semaglutide injection 2.4 mg, in India.
Emcure Pharmaceuticals Ltd, Afcons Infrastructure Ltd, Bata India Ltd, Deepak Fertilisers & Petrochemicals Corp Ltd are among the other stocks to see a surge in volumes on BSE today, 28 October 2025.
Aditya Birla Capital Ltd saw volume of 267.93 lakh shares by 10:47 IST on BSE, a 213.4 fold spurt over two-week average daily volume of 1.26 lakh shares. The stock dropped 0.10% to Rs.310.35. Volumes stood at 97862 shares in the last session.
Emcure Pharmaceuticals Ltd recorded volume of 80999 shares by 10:47 IST on BSE, a 26.16 times surge over two-week average daily volume of 3096 shares. The stock lost 0.35% to Rs.1,344.00. Volumes stood at 2749 shares in the last session.
Afcons Infrastructure Ltd clocked volume of 2.99 lakh shares by 10:47 IST on BSE, a 17.64 times surge over two-week average daily volume of 16950 shares. The stock gained 1.39% to Rs.445.90. Volumes stood at 30020 shares in the last session.
Bata India Ltd clocked volume of 73371 shares by 10:47 IST on BSE, a 12.26 times surge over two-week average daily volume of 5987 shares. The stock lost 3.22% to Rs.1,132.50. Volumes stood at 3079 shares in the last session.
Deepak Fertilisers & Petrochemicals Corp Ltd witnessed volume of 60872 shares by 10:47 IST on BSE, a 10.06 times surge over two-week average daily volume of 6049 shares. The stock increased 3.63% to Rs.1,513.10. Volumes stood at 4548 shares in the last session.